Multiple Sclerosis

Most of the latest Multiple Sclerosis treatments cater to relapsing and remitting MS patients. Until Roche’s blockbuster drug Ocrevus launched for progressive MS, patients with progressive and advanced multiple sclerosis had not benefitted as much from therapeutic innovations in the MS space. Renowned neurologist, Robert Fox indicates that he always is very transparent with newly...

Multiple sclerosis (MS) is an immune-mediated progressive disease that results in chronic inflammation and demyelination of the central nervous system. It leads to physical and cognitive disability, with symptoms including fatigue, gait and visual disturbances, bowl and bladder dysfunction, cognitive dysfunction and mental health symptoms. The exact cause of MS is unknown but is thought to...

Multiple sclerosis affects approximately 400,000 people across the United States and over 2 million people worldwide. [Munoz-Culla 2013; Buchanan 2011] Symptoms of MS include focal signs such as weak motor and sensory deficits, visual disorders, spasticity, bladder and bowel dysfunction, and dysphagia, as well as generalized symptoms, including depression, pain, cognitive difficulties, and fatigue. [Kahn...

A lack of diverse representation of patients in clinical research has made it difficult to adequately assess the unique patient journey and efficacy of treatment for minority MS patients in comparison to non-Hispanic Caucasian women.   According to a recent study published earlier this year in Multiple Sclerosis and Demyelinating Disorders. The African-American population in...